Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens

Cancer Research

Volumn 63, Issue 6, 2003, Pages 1188-1191

  Balz, Vera ^a   Scheckenbach, Kathrin ^a   Götte, Karl ^b   Bockmühl, Ulrike ^c   Petersen, Iver ^d   Bier, Henning ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c General Hospital   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN P53;

ARTICLE; CARCINOGENESIS; CODING; CONTROLLED STUDY; EXON; HEAD AND NECK CANCER; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SQUAMOUS CELL CARCINOMA; WART VIRUS; WILD TYPE;

CARCINOMA, SQUAMOUS CELL; DNA-BINDING PROTEINS; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; MALE; ONCOGENE PROTEINS, VIRAL; POINT MUTATION; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0037444398     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Sidransky, D. Molecular genetics of head and neck cancer. Curr. Opin. Oncol., 7: 229-233, 1995.
2. Gillison, M. L., Koch, W. M., Capone, R. B., Spafford, M., Westra, W. H., Wu, L., Zahurak, M. L., Daniel, R. W., Viglione, M., Symer, D. E., Shah, K. V., and Sidransky, D. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl. Cancer Inst. (Bethesda), 92: 709-720, 2000.
3. Raybaud-Diogène, H., Tétu, B., Morency, R., Fortin, A., and Monteil, R. A. p53 overexpression in head and neck squamous cell carcinoma: review of the literature. Eur. J. Cancer B Oral Oncol., 32B: 143-149, 1996.
4. Saunders, M. E., Mac Kenzie, R., Shipman, R., Fransen, E., Gilbert, R., and Jordan, R. C. K. Patterns of p53 mutations in head and neck cancer: full-length gene sequencing and results of primary radiotherapy. Clin. Cancer Res., 5: 2455-2463, 1999.
5. Thomas, M., Pim, D., and Banks, L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene, 18: 7690-7700, 1999.
6. Franceschi, S., Munoz, N., and Snijders, P. J. How strong and how wide is the link between HPV and oropharyngeal cancer? Lancet, 356: 871-872, 2000.
7. Hauser, U., Balz, V., Carey, T. E., Grénman, R., van Lierop, A., Scheckenbach, K., and Bier, H. Reliable detection of p53 aberrations in squamous cell carcinomas of the head and neck requires transcript analysis of the entire coding region. Head Neck, 24: 868-873, 2002.
8. Murakami, Y., Hayashi, K., and Sekiya, T. Detection of aberrations of the p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis. Cancer Res., 51: 3356-3361, 1991.
9. Prives, C., and Hall, P. A. The p53 pathway. J. Pathol., 187: 112-126, 1999.
10. Soussi, T., and Béroud, C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat. Rev. Cancer, 1: 233-240. 2001.
11. Fisher, D. E. The p53 tumor suppressor: critical regulator of life and death in cancer. Apoptosis, 6: 7-15, 2001.
12. Robles, A. I., Linke, S. P., and Harris, C. C. The p53 network in lung carcinogenesis. Oncogene, 21: 6898-6907, 2002.
13. Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., and Hancock, D. C. Induction of apoptosis in fibroblasts by c-myc protein. Cell, 69: 119-128, 1992.
14. Hickman, J. A. Apoptosis and tumorigenesis. Curr. Opin. Genet. Dev., 12: 67-72, 2002.
15. Sisk, E. A., Soltys, S. G., Zhu, S., Fisher, S. G., Carey, T. E., and Bradford, C. R. Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck, 24: 841-849, 2002.
16. Eicheler, W., Zips, D., Dörfler, A., Grénman, R., and Baumann, M. Splicing mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection. J. Histochem. Cytochem., 50: 197-204, 2002.
17. Kropveld, A., Rozemuller, E. H., Leppers, F. G. J., Scheidel, K. C., de Weger, R. A., Koole, R., Hordijk, G. J., Slootweg, P. J., and Tilanus, M. G. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers. Lab. Investig., 79: 347-353. 1999.
18. Williams, C., Norberg, T., Ahmadian, A., Pontén, F., Bergh, J., Inganäs, M., Lundeberg, J., and Uhlén, M. Assessment of sequence-based p53 gene analysis in human breast cancer: messenger RNA in comparison with genomic DNA targets. Clin. Chem., 44: 455-462, 1998.
19. Storey, A., Thomas, M., Kalita, A., Harwood, C., Gardiol, D., Mantovani, F., Breuer, J., Leigh, I. M., Matlashewski, G., and Banks, L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature, 393: 229-234, 1998.
20. Thomas, M., Kalita, A., Labrecque, S., Pim, D., Banks, L., and Matlashewski, G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell. Biol., 19: 1092-1100, 1999.
21. Beckman, G., Birgander, R., Själander, A., Saha, N., Holmberg, P. A., Kivelä, A., and Beckman, L. Is p53 polymorphism maintained by natural selection? Hum. Hered., 44: 266-270, 1994.
22. Erber, R., Conradt, C., Homann, N., Enders, C., Finckh, M., Dietz, A., Weidauer, H., and Bosch, F. X. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene, 16: 1671-1679, 1998.
23. 264-272 peptide in cancer patients: implications for immunoselection of epitope loss variants. J. Immunol., 165: 5938-5944, 2000.
24. Hilsenbeck, S. G., Clark, G. M., Mc Guire, W. L. Why do so many prognostic factors fail? Breast Cancer Res. Treat., 22: 197-206, 1992.
25. Schumacher, M., Holländer, N., Schwarzer, G., and Sauerbrei, W. Prognostic factor studies. In: J. Crowley (ed.), Handbook of Statistics in Clinical Oncology, pp. 312-378. New York: Marcel Dekker, 2001.
26. Chen, H. L., and Carbone, D. P. p53 as a target for anti-cancer immunotherapy. Mol. Med. Today, 3: 160-167, 1997.
27. Gallagher, W. M., and Brown, R. p53-oriented cancer therapies: current progress. Ann. Oncol., 10: 139-150, 1999.